Načítá se...
Advances in antibody–drug conjugates: a new era of targeted cancer therapy
Antibody–drug conjugates (ADCs), a potent class of anticancer therapeutics, comprise a high-affinity antibody (Ab) and cytotoxic payload coupled via a suitable linker for selective tumor cell killing. In the initial phase of their development, two ADCs, Mylotarg®, and Adcetris® were approved by the...
Uloženo v:
| Vydáno v: | Drug Discov Today |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6944323/ https://ncbi.nlm.nih.gov/pubmed/28627385 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.drudis.2017.05.011 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|